Understand the source comparison
Cartalax Side Effects vs Other Peptide Bioregulators: Comparison
Researchers often compare cartalax side effects to other short-chain peptide bioregulators to contextualize tolerability. The table below contrasts adverse event profiles across four commonly researched peptides of similar structure and molecular weight. Carta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers often compare cartalax side effects to other short-chain peptide bioregulators to contextualize tolerability. The table below contrasts adverse event profiles across four commonly researched peptides of similar structure and molecular weight.
- Cartalax
- Ala-Glu-Asp tripeptide
- Injection site erythema
- 8–12% per dose
- Very low—no non-native residues
- Best tolerability profile among tripeptide bioregulators; reactions driven by impurities, not pharmacology
- Epitalon
- Ala-Glu-Asp-Gly tetrapeptide
- Transient fatigue
- 15–20% per dose
- Low—endogenous amino acids only
- Slightly higher systemic symptom rate; glycine terminus may contribute to CNS-mediated fatigue
- Thymalin
- Polypeptide complex (>40 residues)
- Injection site induration
- 20–25% per dose
- Moderate—larger epitope presentation
- Higher immune recognition due to size; induration persists 12–24 hours vs 4–8 hours for Cartalax
- Selank
- Met-Glu-His-Phe-Pro-Gly-Pro heptapeptide
- Mild sedation
- 10–15% per dose
- Low—but histidine oxidation creates variants
- Sedation likely GABA-mediated; oxidation byproducts increase reaction variability
- Cartalax's three-residue length and absence of oxidation-prone amino acids (methionine, cysteine, tryptophan) make it one of the most chemically stable and immunologically inert peptides in the bioregulator class. Epitalon Peptide and Thymalin both show elevated injection site reaction rates correlated with longer sequences and greater immune epitope presentation. Researchers prioritizing minimal adverse event profiles in cartilage or musculoskeletal studies consistently favor Cartalax over longer analogs for this reason.